How does KOPN's valuation (P/E, EV/EBITDA, price/ sales) compare to its primary competitors like DLP, Microvision, and Lumentum? | KOPN (Aug 06, 2025) | Candlesense

How does KOPN's valuation (P/E, EV/EBITDA, price/ sales) compare to its primary competitors like DLP, Microvision, and Lumentum?

What the news tells us

The Business Wire release you shared only announces that Kopin Corporation (NASDAQ KOPN) will hold an earnings‑call for its Q2 2025 results on August 12 2025. The release does not include any of the valuation metrics you’re asking about (P/E, EV/EBITDA, price‑to‑sales) nor does it contain the comparable data for DLP (or DLP‑related companies), MicroVision (MVIS), or Lumentum (LUMN).

What that means for your question

Because the required numbers are not present in the provided news article, I’m not able to calculate or compare KOPN’s current valuation multiples to those of its peers. Providing any specific figures (e.g., “KOPN trades at a P/E of X vs. Lumen’s P/E of Y”) would require either:

  1. Recent financial data (latest earnings, market‑cap, shares outstanding, EBITDA, revenue, etc.) from the companies’ most recent quarterly or annual reports, or
  2. Real‑time market data (stock price, enterprise‑value, net‑income, EBITDA, revenue) from a financial data service (Bloomberg, FactSet, S&P Capital IQ, Yahoo Finance, etc.).

Since neither of those sources is included in the announcement, the only responsible answer is to explain that the needed information is not available in the given news item.

How you can obtain the needed numbers

  1. Collect the latest financial statements

    • KOPN – Look at the Q2 2025 earnings release (which will be published before the call) and the FY 2024/2025 10‑K/10‑Q filings.
    • DLP (if you refer to the company that trades under a ticker like DPH or a similar entity), MicroVision (MVIS), and Lumentum (LUMN) – Pull their most recent quarterly or annual reports (10‑Q/10‑K).
  2. Calculate the valuation multiples

| Ratio | Formula | Data needed |
|------|--------|------------|
| P/E | (Current Share Price × Shares Outstanding) Ă· Net Income | Market cap (or share price & shares) + Net income (annualized or quarterly) |
| EV/EBITDA | (Market Cap + Total Debt – Cash) Ă· EBITDA | Market cap, debt, cash, and EBITDA |
| Price‑to‑Sales (P/S) | Market Cap Ă· Annual Revenue | Market cap, annual revenue (or annualized Q2 revenue) |

  1. Use a reliable data source

    • Financial portals (Yahoo Finance, Google Finance, MarketWatch) often list P/E and P/S directly.
    • EV/EBITDA is often shown in Bloomberg, FactSet, or S&P Capital IQ.
    • If you have a brokerage account, you can also pull the “Key Statistics” or “Financial Summary” sections for each ticker.
  2. Benchmark against peers

    • Once you have the three ratios for each company, place them side‑by‑side to see which firm trades at a premium or discount on each metric.
    • Adjust for any structural differences (e.g., KOPN’s higher proportion of defense contracts, MicroVision’s focus on LiDAR‑based micro‑display, Lumentum’s broader telecom‑optical portfolio) that could explain valuation divergences.

Bottom‑line answer

Based solely on the news you provided, there is no information available to compare KOPN’s P/E, EV/EBITDA, or price‑to‑sales multiples to those of DLP, MicroVision, or Lumentum. To make that comparison you’ll need to retrieve the latest financial data for each company (as described above) and compute the ratios.

If you can share the latest earnings data or a snapshot of the relevant financial metrics, I can gladly walk you through the calculation and interpretation of those valuation ratios.

Other Questions About This News

What is the current order backlog and pipeline for the next 12‑18 months, especially regarding defense contracts and long‑term government agreements? What is the current cash balance, debt level, and liquidity position, and are there any covenants or financing milestones upcoming? How did the stock price react to the prior quarter’s earnings release, and what is the market’s current sentiment toward KOPN? What were the capital expenditure, R&D spending, and cash flow figures for the quarter, and how do they affect the balance sheet? What were the gross margin and operating margin for Q2, and how do they compare to prior periods and industry peers? Did the company experience any supply‑chain or component shortages that impacted production or margins? What is the outlook for the microdisplay and optical systems markets in 2025‑2026, and how is KOPN positioned relative to peers? What risks were highlighted by management (e.g., regulatory, geopolitical, customer concentration) that could impact future earnings? What were the revenue, net income, and earnings per share for Q2 2025, and how do they compare to the prior quarter and year‑over‑year? Did management provide guidance for Q3 2025 and full‑year 2025, and how does it compare to consensus estimates? Did the company announce any new contracts, partnerships, or product launches during the quarter? What were the key drivers of revenue growth or decline (e.g., defense contracts, training systems, medical devices) in Q2 2025? How did each business segment (defense, training, enterprise, industrial, consumer, medical) perform in terms of revenue, margin, and order backlog? Is there any discussion about potential share buybacks, dividend policy, or other capital return strategies?